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Monitor
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Background: Progesterone rises ∼24–36 h after ovulation. Past studies using
ultrasound-confirmed ovulation have shown that three consecutive tests with a threshold
of 5 µg/mL of urine progesterone (pregnanediol-3-glucuronide, PDG), taken after the
luteinizing hormone (LH) surge, confirmed ovulation with 100% specificity.
Purpose: The purpose of this study was to a evaluate a new urine PDG self-test
to retrospectively confirm ovulation in women who were monitoring ovulation using a
hormonal fertility monitor.
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Methods: Thirteen women of reproductive age were recruited to test urine PDG while
using their home hormonal fertility monitor. The monitor measured the rise in estrogen
(estrone-3-glucuronide, E3G) and LH to estimate the fertile phase of the menstrual cycle.
The women used an online menstrual cycle charting system to track E3G, LH and PDG
levels for four menstrual cycles.
Results: The participants (Mean age 33.6) produced 34 menstrual cycles of data (Mean
length 28.4 days), 17 of which used a PDG test with a threshold of 7 µg/mL and 17 with a
threshold of 5 µg/mL. In the cycles that used the 7µg/mL test strips, 59% had a positive
confirmation of ovulation, and with the 5 µg/mL test strips, 82% of them had a positive
confirmation of ovulation.
Conclusion: The 5 µg/mL PDG test confirmed ovulation in 82% of cycles and could
assist women in the evaluation of the luteal progesterone rise of their menstrual cycle.
Keywords: natural family planning, progesterone, fertility monitoring, ovulation, ovulation confirmation

INTRODUCTION
Teaching women to monitor their menstrual cycle can empower them to understand their
reproductive health in order to facilitate or avoid pregnancy (1–3). Women have been able to
monitor estrone-3-glucuronide (E3G) and luteinizing hormone (LH) at home in their urine
using test sticks and fertility monitors for several decades, but monitoring urine pregnanediol-3glucuronide (PDG, the urine metabolite of progesterone) has been very limited. The most common
way to assess the luteal phase and confirm ovulation has been to take daily first morning basal body
temperatures to track a significant rise from baseline. This temperature method is time consuming
and often inaccurate (4). Confirming ovulation with a serum progesterone test (5) requires a
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contributed from 1 to 4 menstrual cycles of data. The volunteer
women users or teachers of the Marquette Method were sent the
PDG test strips (test strips for both 7 and 5 µg/mL thresholds)
and given instructions to use the strips for 1–4 menstrual
cycles and to chart the results in the Marquette Method online
charting system.
Inclusion criteria were: (1) regular menstrual cycles, (2) at
least 3 menstrual cycles after cessation of breastfeeding, (3)
age 20–46, (4) a Marquette Method provider or user using
a Clearblue Easy Fertility Monitor (CBEFM), (5) willing to
complete one to four menstrual cycles of testing, and (6)
willing to provide us with completed menstrual cycle charts
using the CBEFM and the urine PDG tests. Exclusion criteria
were: (1) a history of polycystic ovarian syndrome or (2) subfertility. Participants were given 6 months free use of the online
charting site.
The volunteer participants were asked to follow the following
protocol which was approved through the Marquette University’s
Institutional Review Board (IRB):

physician order and going to the laboratory to draw blood,
which is expensive and time consuming. A fertility monitor
measuring PDG has been developed since the 1980s by Brown
and colleagues (6) but these devices are currently not widely
available (7).
A new urine PDG test (Progesterone Ovulation Test “Proov,”
https://proovtest.com) is now commercially available and is
currently being used by women, including users of the Marquette
Method, to evaluate their progesterone status. The Marquette
Method is a Fertility Awareness Based Method (FABM) that
uses the ClearBlue Easy Fertility Monitor (CBEFM) to monitor
urinary hormones of the menstrual cycle with an online
education and charting application (nfp.marquette.edu). The
CBEFM measures the rise in E3G and the surge in LH to
estimate the fertile phase of the menstrual cycle (8, 9). In order to
understand and educate users on the utility and accuracy of the
new PDG test stick, we undertook the current pilot study of the
PDG test strip using a simple protocol. The protocol was tested
by Marquette Method health professionals (i.e., physicians and
professional nurses), providers and users.
The new PDG test strip indicates when a threshold level
of progesterone has been reached after a Luteinizing Hormone
(LH) surge and/or the peak of cervical mucus. The threshold
level of progesterone detected by the PDG test strip was based
upon a research study (10) that evaluated urinary levels of PDG
after a luteinizing hormone (LH) surge or the peak of cervical
mucus. It was found that ultrasound-confirmed ovulation could
be identified retrospectively with 100% specificity when urinary
PDG thresholds were more than 5 µg/mL for three consecutive
days following an LH surge or peak mucus (10).
The purpose of this pilot study was to test the use of the
new urine PDG tests by comparing the new test’s confirmation
of ovulation with the CBEFM’s detection of the LH surge.
The developers of the ClearBlue monitor have demonstrated
the strong correlation between ovulation and the LH surge
(11), and in the present study, sensitivity of the PDG assay
in confirming ovulation is based on the LH surge, which is a
reliable surrogate for ovulation. The LH surge occurs 24–36 h
before ovulation (12) and was used to determine the percentage
of positive PDG tests that occurred after the LH surge. This
was a feasibility pilot study of the use of the new PDG test
strip and there is only one other study that we are aware of
looking at the feasibility of the use of this test for women’s cycles.
Before we can recommend the use and accuracy of this test
strip for Marquette Method users, we wanted to demonstrate
a level of evidence in the field that the manufacturer has not
yet produced.

1. On the morning of the second Peak LH reading of the monitor
use the PDG test with your first morning urine collected and
tested in a container (not within the urine stream).
2. Continue to use the PDG test with the first morning urine until
you have three positive tests in a row (Note that three positive
tests in a row is a confirmation of ovulation).
3. If you think you have a missed LH surge with the monitor do
not use the PDG test that cycle; wait until the next cycle when
you have a peak on the monitor.
4. Record the results on the bottom (“Mucus”) line of the online
chart (Figure 1), and record a positive test as “P” and a
negative test as “L.”
The use of the “Mucus” line on the online chart was to
facilitate recording in the current online charting system
without having to create an entirely new charting system
for the PDG result (Figure 1). The indicators “P” and “L”
refer to “Peak” and “Low,” respectively, and are used as
descriptors for the Mucus rating scale in the ordinary use of the
Marquette Method.

RESULTS
The 13 volunteer participants (Mean age 33.6; SD = 6.4; range
26–46) produced 34 menstrual cycles of data (Mean length 28.4
days; SD = 2.1; range = 23–32 days). The luteal phase of our
participants ranged from 10 to 16 days.
There were 17 menstrual cycles of data using test sticks for
each of the 7 and 5 µg/mL thresholds (Table 1). Only 59% (10 of
17) of the menstrual cycles that used the 7 µg/mL test strips had a
positive PDG test while 82.4% (14 of 17) had a positive PDG test
using the 5 µg/mL test strips (Table 1).
The positive PDG tests occurred from 2 to 10 days after
the second Peak reading of LH on the monitor, with the most
frequent positive results on days 4 and 5 past the surge. However,
all 14 of the menstrual cycles that had a positive PDG with the
5 µg/mL test strips had a narrower window, occurring from 2 to

METHODOLOGY
Marquette Method providers and users who use an online
menstrual cycle charting system volunteered for the study.
The providers were sent an e-mail asking them to consider
participating in a study to test the new PDG test strips. We
planned to recruit initially only 10 participants, but 17 women
agreed to participate and signed a consent form, 13 of whom
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FIGURE 1 | Example charts showing three positive PDG tests (on the mucus line) after the LH surge (P for Peak) detected by the ClearBlue Easy Fertility Monitor.
L, negative test; P, positive test. On the Monitor Line, L, Low; H, High; P, Peak fertility based on E3G and LH results from the CBEFM.

The main limitation of our study was the small sample size
with only 13 participants and 34 menstrual cycles of use. Having
a larger number of participants that use the PDG test strips
for 7 days or more is recommended. While the gold standard
to identify ovulation is the use of ultrasound, as mentioned
LH as measured by the CBEFM has a strong correlation
with ovulation as demonstrated by established reference
ranges (11).
Many women have started to use the new PDG test trips
for various reasons; however, the main reason is to assist
with achieving pregnancy. The PDG tests provide women
with evidence that they have ovulated and have adequate
progesterone levels and luteal phases that are long enough
to support a pregnancy. Women who use FABMs to avoid
pregnancy could also use the PDG test as a double check
method for confirming the end of the fertile phase. The PDG
tests could also be useful for women who have polycystic
ovarian syndrome, have difficulty identifying their LH surge
or peak mucus, are in postpartum amenorrhea and want to
confirm their first ovulation, and women in perimenopause
who want to confirm they are still ovulating. These applications
have been evaluated before by others who have been able
to measure PDG in the urine (6, 7), and require further
follow-up with newer devices to identify whether these are
viable applications for home PDG measurement. At present,
the confirmation of ovulation in only 80% of the women in
this study makes the practical value of the test still open to
further investigation.
The urine PDG test is another way for women to test their
hormones at home to determine if they have ovulated. Currently,
there are PDG test strips in devolopment that can be interpreted
by smart phone cameras rather than the subjectivity of the
naked eye. Quantitative PDG tests are also being developed and
should be available in the near future.

TABLE 1 | Frequency of positive PDG tests (5 and 7 µg/mL) in days after the
LH surge.
Days Past LH Surge

5 ug/mL

7 ug/mL

1

2

1

2

1

2

3

6

4

4

5

1

5

0

1

6

0

0

7

0

0

8

0

1

9

0

1

Total Positive Tests

14

11

Negative Tests

3

7

Total Tests

17

18

Percentage

82%

59%

5 days past the LH surge with the most frequent positive test on
days 4 and 5 (see Table 1). Confidence intervals (95%) were 0.64
to 1.00 for the 5 µg/mL test and 0.36 to 0.82 for the 7 µg/mL test.

DISCUSSION
We found that the urine PDG test strips with the 5 µg/mL
threshold detected the progesterone after the LH surge just over
80% of the time, compared to ∼60% detection frequency for the
PDG rise with the 7 µg/mL. Given these results, the newer lower
threshold is more appropriate for clinical use. It should be noted
that some older reproductive age women in the study might have
lower post ovulation progesterone levels that may contribute to
some of the negative tests.
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